Summary
Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic diseases, respiratory diseases, immune disorders and infections, among others. The company offers eye care products through its subsidiary, Alcon; and generic medicines through Sandoz. Novartis carries out research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
Novartis AG (NOVN) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Novartis AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Novartis AG, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Novartis AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Novartis AG, Medical Equipment, Deals By Market, 2011 to YTD 2017 11
Novartis AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Novartis AG, Medical Equipment, Deal Details 20
Venture Financing 20
Lemonaid Health Raises USD11 Million in Series A Financing 20
Atlas Genetics Raises USD35 Million in Series D Financing 20
Seventh Sense Biosystems Raises USD10 Million in Series C Financing 22
Rox Medical Raises USD40 Million in Series E Financing 24
Cota Raises Funds through Venture Financing 25
Ra Pharma Raises USD58.5 Million in Series B Financing 26
Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 26
MyoPowers Medical Raises USD5 Million in Venture Financing 28
Autonomic Technologies Raises USD38 Million in Series D Financing 29
Merganser Biotech Raises USD28 Million in Series A Financing 30
Encore Vision Raises USD1 Million in Venture Financing 31
Atlas Genetics Raises USD20 Million in Series C Financing 31
Transcend Medical Raises USD7.2 Million in Venture Financing 33
BioNano Genomics Raises USD53 Million in Series C Venture Financing 33
Seventh Sense Biosystems Raises USD16 Million in Series B Financing 34
ImaginAb Raises US$21 Million In Series B Venture Financing 36
Transcend Medical Raises US$22 Million In Series C Venture Financing 37
Wavetec Vision Systems Raises US$0.8 Million In Venture Financing 38
Encore Vision Secures USD5 Million in Venture Funding 38
Wavetec Vision Raises US$11 Million In Series D-2 Financing 39
Proteus Digital Health Raises US$63 Million In Series F Financing Round 40
Health XL Raises Funds Through Venture Financing 41
Wavetec Vision Raises US$16.5 Million In Venture Financing 42
Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 43
ImaginAb Raises US$12.5 Million In Series A Financing 43
WaveTec Vision Raises US$1.5 Million In Venture Financing 44
Transcend Medical Secures USD16 Million in Series B Venture Funding 45
Autonomic Technologies Secures US$32 Million In Series C Venture Financing 46
Atlas Genetics Raises US$27 Million In Series B Financing 47
Transcend Medical Secures Additional US$15 Million In Series B Venture Financing 49
MyoPowers Medical Secures US$18.9 Million In Series B Financing 50
Sorbent Therapeutics Secures An Additional US$36 Million In Series B Venture Financing 51
WaveTec Vision Secures US$15.9 Million In Series D Venture Financing Round 52
Wavetec Vision Raises US$3.5 Million In Venture Financing 53
Private Equity 54
dievini Hopp BioTech to Acquire Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 54
Partnerships 55
Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 55
Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 55
Camurus Exercises Option For Licensing Agreement With Novartis For Octreotide 56
IRIDEX Enters Into Licensing Agreement With Alcon 57
OctreoPharm Sciences Enters Into Licensing Agreement With Novartis Pharma For SOMscan 58
Propeller Health Enters into Agreement with Novartis Pharma 59
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 59
Novartis Enters into Agreement with Microsoft 60
MedinCell Enters into Agreement with Sandoz International 61
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 62
CorTechs Labs Enters into Agreement with Novartis Pharma 63
Qiagen Enters into Co-Development Agreement with Novartis 63
SomaLogic Extends Co-Development Agreement with Novartis 64
MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 65
Foundation Medicine Expands Co-Development Agreement With Novartis 66
Foundation Medicine Extends Co-Development Agreement With Novartis 67
Grifols Enters Into Co-Marketing Agreement With Novartis 67
Foundation Medicine Enters Into An Agreement With Novartis 68
Sunovion Pharma Enters into Licensing Agreement with Novartis 69
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 70
Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 70
Life Technologies Enters Into Licensing Agreement With Novartis 71
Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 72
Debt Offering 73
Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 73
Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 73
Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 74
Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 75
Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For US$1.5 Billion 76
Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For US$500 Million 77
Asset Transactions 78
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 78
Novartis Plans to Divest Assets of Alcon 79
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 79
Acquisition 81
GlaxoSmithKline May Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD10.3 Billion 81
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 82
Alcon to Acquire Transcend Medical 83
Novartis May Acquire Genfit 84
Novartis Acquires Ziarco Group 85
Novartis Acquires Encore Vision 86
Novartis Plans to Sell its Stake in F. Hoffmann-La Roche 87
Alcon Acquires WaveTec Vision Systems 87
Novartis Acquires Vivacta For US$90 Million 89
Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 90
Novartis Completes Acquisition Of Remaining 23% Stake In Alcon 91
Novartis AG - Key Competitors 94
Key Employees 95
Locations And Subsidiaries 97
Head Office 97
Other Locations & Subsidiaries 97
Recent Developments 116
Strategy And Business Planning 116
May 25, 2016: Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event 116
Financial Announcements 118
Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 118
Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 122
Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 128
Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects 134
Apr 21, 2016: Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth 140
Jan 27, 2016: Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations 145
Corporate Communications 153
May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 153
Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 154
Other Significant Developments 155
Jun 05, 2017: Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer 155
Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 156
Jan 26, 2017: Achievement of sales milestone for COPD products 157
Jan 25, 2017: Seebri / Ultibro Breezhaler 2016 sales reach $512 million triggering $5 million milestone receipt 158
Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda 159
May 24, 2016: COTA Increases Cross-Industry Support With the Addition of Celgene, Foundation Medicine HealthScape Advisors and Novartis as Strategic Investors 160
May 17, 2016: Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis 161
Mar 31, 2016: Novartis publishes updated 2015 segment financials reflecting new division structure 162
Appendix 163
Methodology 163
About GlobalData 163
Contact Us 163
Disclaimer 163
List of Tables
Novartis AG, Medical Equipment, Key Facts, 2016 1
Novartis AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
Novartis AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Novartis AG, Medical Equipment Deals By Type, 2011 to YTD 2017 9
Novartis AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Novartis AG, Deals By Market, 2011 to YTD 2017 11
Novartis AG, Medical Equipment, Deals Summary, 2011 to YTD 2017 12
Lemonaid Health Raises USD11 Million in Series A Financing 20
Atlas Genetics Raises USD35 Million in Series D Financing 20
Seventh Sense Biosystems Raises USD10 Million in Series C Financing 22
Rox Medical Raises USD40 Million in Series E Financing 24
Cota Raises Funds through Venture Financing 25
Ra Pharma Raises USD58.5 Million in Series B Financing 26
Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 26
MyoPowers Medical Raises USD5 Million in Venture Financing 28
Autonomic Technologies Raises USD38 Million in Series D Financing 29
Merganser Biotech Raises USD28 Million in Series A Financing 30
Encore Vision Raises USD1 Million in Venture Financing 31
Atlas Genetics Raises USD20 Million in Series C Financing 31
Transcend Medical Raises USD7.2 Million in Venture Financing 33
BioNano Genomics Raises USD53 Million in Series C Venture Financing 33
Seventh Sense Biosystems Raises USD16 Million in Series B Financing 34
ImaginAb Raises US$21 Million In Series B Venture Financing 36
Transcend Medical Raises US$22 Million In Series C Venture Financing 37
Wavetec Vision Systems Raises US$0.8 Million In Venture Financing 38
Encore Vision Secures USD5 Million in Venture Funding 38
Wavetec Vision Raises US$11 Million In Series D-2 Financing 39
Proteus Digital Health Raises US$63 Million In Series F Financing Round 40
Health XL Raises Funds Through Venture Financing 41
Wavetec Vision Raises US$16.5 Million In Venture Financing 42
Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 43
ImaginAb Raises US$12.5 Million In Series A Financing 43
WaveTec Vision Raises US$1.5 Million In Venture Financing 44
Transcend Medical Secures USD16 Million in Series B Venture Funding 45
Autonomic Technologies Secures US$32 Million In Series C Venture Financing 46
Atlas Genetics Raises US$27 Million In Series B Financing 47
Transcend Medical Secures Additional US$15 Million In Series B Venture Financing 49
MyoPowers Medical Secures US$18.9 Million In Series B Financing 50
Sorbent Therapeutics Secures An Additional US$36 Million In Series B Venture Financing 51
WaveTec Vision Secures US$15.9 Million In Series D Venture Financing Round 52
Wavetec Vision Raises US$3.5 Million In Venture Financing 53
dievini Hopp BioTech to Acquire Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 54
Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 55
Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 55
Camurus Exercises Option For Licensing Agreement With Novartis For Octreotide 56
IRIDEX Enters Into Licensing Agreement With Alcon 57
OctreoPharm Sciences Enters Into Licensing Agreement With Novartis Pharma For SOMscan 58
Propeller Health Enters into Agreement with Novartis Pharma 59
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 59
Novartis Enters into Agreement with Microsoft 60
MedinCell Enters into Agreement with Sandoz International 61
Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 62
CorTechs Labs Enters into Agreement with Novartis Pharma 63
Qiagen Enters into Co-Development Agreement with Novartis 63
SomaLogic Extends Co-Development Agreement with Novartis 64
MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 65
Foundation Medicine Expands Co-Development Agreement With Novartis 66
Foundation Medicine Extends Co-Development Agreement With Novartis 67
Grifols Enters Into Co-Marketing Agreement With Novartis 67
Foundation Medicine Enters Into An Agreement With Novartis 68
Sunovion Pharma Enters into Licensing Agreement with Novartis 69
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 70
Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 70
Life Technologies Enters Into Licensing Agreement With Novartis 71
Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 72
Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 73
Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 73
Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 74
Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 75
Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For US$1.5 Billion 76
Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For US$500 Million 77
China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 78
Novartis Plans to Divest Assets of Alcon 79
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 79
GlaxoSmithKline May Acquire Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD10.3 Billion 81
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 82
Alcon to Acquire Transcend Medical 83
Novartis May Acquire Genfit 84
Novartis Acquires Ziarco Group 85
Novartis Acquires Encore Vision 86
Novartis Plans to Sell its Stake in F. Hoffmann-La Roche 87
Alcon Acquires WaveTec Vision Systems 87
Novartis Acquires Vivacta For US$90 Million 89
Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 90
Novartis Completes Acquisition Of Remaining 23% Stake In Alcon 91
Novartis AG, Key Competitors 94
Novartis AG, Key Employees 95
Novartis AG, Subsidiaries 97
List of Figures
Novartis AG, Medical Equipment, Deals by Type, 2011 to YTD 2017 1
Novartis AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 1
Novartis AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 1
Novartis AG, Medical Equipment, Deals By Market, 2011 to YTD 2017 1
Novartis AG, Medical Equipment, Deals By Year, 2011 to YTD 2017 8
Novartis AG, Medical Equipment, Deals by Type, 2011 to YTD 2017 9
Novartis AG, Medical Equipment, Deals By Region, 2011 to YTD 2017 10
Novartis AG, Medical Equipment, Deals by Market, 2011 to YTD 2017 11
